EU Draft Guidelines On Biosimilar Antibodies Go Easy On Generics Firms, But Originators Need Not Panic
This article was originally published in The Pink Sheet Daily
Executive Summary
Guidelines say clinical efficacy trials may not always be required, but leaves significant scope to treat applications on a case-by-case basis.